West Pharmaceutical Services INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NYSE
West Pharmaceutical Services reports strong Q2 2026 results with significant revenue and profit growth, driven by its Proprietary Products segment.
NYSE
West Pharmaceutical Services reports a significant increase in net sales and operating profit for Q1 2026, driven by strong performance in its Proprietary Products segment.
NYSE
West Pharmaceutical Services reports robust Q3 2025 sales and margin expansion, alongside ongoing restructuring and a securities class action.
NYSE
West Pharmaceutical Services, Inc. announced robust second-quarter financial results, showcasing significant net sales and operating profit growth, primarily fueled by its Proprietary Products segment and improved gross profit margins.
NYSE
10-Q: West Pharmaceutical Services Reports Q1 2025 Results: Sales Slightly Up, Restructuring Plan Approved
West Pharmaceutical Services reports a slight increase in net sales for Q1 2025, while initiating a restructuring plan to optimize operating costs.
NYSE
West Pharmaceutical Services experienced a slight decrease in net sales and a notable decline in gross profit for the third quarter of 2024, impacted by customer inventory management and a shift in product mix.
NYSE
West Pharmaceutical Services experienced a decrease in net sales and operating profit in the second quarter of 2024, primarily due to customer inventory management and unfavorable product mix.
NYSE
West Pharmaceutical Services experienced a decrease in net sales and operating profit in the first quarter of 2024 compared to the same period last year, primarily due to lower sales volume and unfavorable product mix.